OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study
Axel De Greef, Pierre‐Dominique Ghislain, Audrey Bulinckx, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 4, pp. 299-306
Open Access | Times Cited: 23
Axel De Greef, Pierre‐Dominique Ghislain, Audrey Bulinckx, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 4, pp. 299-306
Open Access | Times Cited: 23
Showing 23 citing articles:
Atopic Dermatitis: Disease Features, Therapeutic Options, and a Multidisciplinary Approach
Liborija Lugović‐Mihić, Jelena Meštrović-Štefekov, Ines Potočnjak, et al.
Life (2023) Vol. 13, Iss. 6, pp. 1419-1419
Open Access | Times Cited: 29
Liborija Lugović‐Mihić, Jelena Meštrović-Štefekov, Ines Potočnjak, et al.
Life (2023) Vol. 13, Iss. 6, pp. 1419-1419
Open Access | Times Cited: 29
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis
Amalie Thorsti Møller Rønnstad, Christopher G. Bunick, Raj Chovatiya, et al.
American Journal of Clinical Dermatology (2025)
Closed Access | Times Cited: 1
Amalie Thorsti Møller Rønnstad, Christopher G. Bunick, Raj Chovatiya, et al.
American Journal of Clinical Dermatology (2025)
Closed Access | Times Cited: 1
Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: A multicentre study of 12 patients
F.J. Navarro‐Triviño, María Salazar‐Nievas, Juan Luís Sanz-Cabanillas, et al.
Australasian Journal of Dermatology (2024) Vol. 65, Iss. 3, pp. 260-265
Closed Access | Times Cited: 6
F.J. Navarro‐Triviño, María Salazar‐Nievas, Juan Luís Sanz-Cabanillas, et al.
Australasian Journal of Dermatology (2024) Vol. 65, Iss. 3, pp. 260-265
Closed Access | Times Cited: 6
Effectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study
Ersilia Tolino, Luca Ambrosio, Nicoletta Bernardini, et al.
Dermatology and Therapy (2025)
Open Access
Ersilia Tolino, Luca Ambrosio, Nicoletta Bernardini, et al.
Dermatology and Therapy (2025)
Open Access
Long-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice
Anne R. Schlösser, Lars Nijman, Renske Schappin, et al.
Acta Dermato Venereologica (2025) Vol. 105, pp. adv41504-adv41504
Open Access
Anne R. Schlösser, Lars Nijman, Renske Schappin, et al.
Acta Dermato Venereologica (2025) Vol. 105, pp. adv41504-adv41504
Open Access
Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study
Laura Marina Calabrese, Élisa Cinotti, Martina D’Onghia, et al.
Acta Dermato Venereologica (2025) Vol. 105, pp. adv42275-adv42275
Open Access
Laura Marina Calabrese, Élisa Cinotti, Martina D’Onghia, et al.
Acta Dermato Venereologica (2025) Vol. 105, pp. adv42275-adv42275
Open Access
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
Fabrizio Martora, Cataldo Patruno, Silvia D’Ascenzo, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 3
Fabrizio Martora, Cataldo Patruno, Silvia D’Ascenzo, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 3
Effectiveness of dupilumab in tralokinumab‐resistant patients with atopic dermatitis: A real‐world experience from two referral centres
Gianluca Tavoletti, Alessandra Chiei Gallo, Luigi Gargiulo, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 3
Gianluca Tavoletti, Alessandra Chiei Gallo, Luigi Gargiulo, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 3
Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations
Luca Potestio, Cataldo Patruno, Stefano Dastoli, et al.
Journal of Asthma and Allergy (2024) Vol. Volume 17, pp. 791-799
Open Access | Times Cited: 3
Luca Potestio, Cataldo Patruno, Stefano Dastoli, et al.
Journal of Asthma and Allergy (2024) Vol. Volume 17, pp. 791-799
Open Access | Times Cited: 3
Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response Factors
Luca Potestio, Cataldo Patruno, Maddalena Napolitano
Dermatitis (2023) Vol. 35, Iss. S1, pp. S77-S80
Closed Access | Times Cited: 8
Luca Potestio, Cataldo Patruno, Maddalena Napolitano
Dermatitis (2023) Vol. 35, Iss. S1, pp. S77-S80
Closed Access | Times Cited: 8
Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond
Eden David, Kelly Hawkins, Neda Shokrian, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 6, pp. 471-489
Closed Access | Times Cited: 3
Eden David, Kelly Hawkins, Neda Shokrian, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 6, pp. 471-489
Closed Access | Times Cited: 3
Tralokinumab improves clinical scores in adolescents with severe atopic dermatitis: A real‐life multicentric observational study
Axel De Greef, Pierre‐Dominique Ghislain, Laurence de Montjoye, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 3
Open Access | Times Cited: 7
Axel De Greef, Pierre‐Dominique Ghislain, Laurence de Montjoye, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 3
Open Access | Times Cited: 7
Interleukin antagonists for atopic dermatitis: a new era of therapy
Aikaterini Tsiogka, Eleni Paschou, Dimitra Koumaki, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 6, pp. 549-559
Closed Access | Times Cited: 2
Aikaterini Tsiogka, Eleni Paschou, Dimitra Koumaki, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 6, pp. 549-559
Closed Access | Times Cited: 2
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study
Andrea Chiricozzi, Silvia Ferrucci, Lucia Di Nardo, et al.
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 12, pp. 1307-1315
Closed Access | Times Cited: 5
Andrea Chiricozzi, Silvia Ferrucci, Lucia Di Nardo, et al.
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 12, pp. 1307-1315
Closed Access | Times Cited: 5
The Role of Tralokinumab in the Treatment of Atopic Dermatitis and Future Perspectives for Adolescents
Adaora Ewulu, Stuti Prajapati, Steven R. Feldman
Immunotherapy (2023) Vol. 15, Iss. 16, pp. 1341-1349
Closed Access | Times Cited: 4
Adaora Ewulu, Stuti Prajapati, Steven R. Feldman
Immunotherapy (2023) Vol. 15, Iss. 16, pp. 1341-1349
Closed Access | Times Cited: 4
Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects
Miguel Antonio Lasheras‐Pérez, Rodolfo David Palacios‐Diaz, Mónica Pozuelo‐Ruiz, et al.
International Journal of Dermatology (2023) Vol. 63, Iss. 1, pp. 105-107
Closed Access | Times Cited: 4
Miguel Antonio Lasheras‐Pérez, Rodolfo David Palacios‐Diaz, Mónica Pozuelo‐Ruiz, et al.
International Journal of Dermatology (2023) Vol. 63, Iss. 1, pp. 105-107
Closed Access | Times Cited: 4
Tralokinumab‐induced injection‐site reactions
Axel De Greef, Marie Baeck
Contact Dermatitis (2024) Vol. 91, Iss. 6, pp. 521-522
Closed Access | Times Cited: 1
Axel De Greef, Marie Baeck
Contact Dermatitis (2024) Vol. 91, Iss. 6, pp. 521-522
Closed Access | Times Cited: 1
Single‐centre experience with tralokinumab in dupilumab‐experienced and naïve patients with atopic dermatitis
Claire Fossati, Emmanuella Guenova, Curdin Conrad, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Open Access | Times Cited: 1
Claire Fossati, Emmanuella Guenova, Curdin Conrad, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Open Access | Times Cited: 1
The Efficacy and Effectiveness of the Biological Treatment of Pruritus in the Course of Atopic Dermatitis
Agnieszka Hołdrowicz, Anna Woźniacka
Journal of Clinical Medicine (2024) Vol. 13, Iss. 6, pp. 1754-1754
Open Access | Times Cited: 1
Agnieszka Hołdrowicz, Anna Woźniacka
Journal of Clinical Medicine (2024) Vol. 13, Iss. 6, pp. 1754-1754
Open Access | Times Cited: 1
Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study
Alexandre Beyrouti, Juliette Deuze, Éric Fontas, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024)
Closed Access
Alexandre Beyrouti, Juliette Deuze, Éric Fontas, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024)
Closed Access
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28‐Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels
Coco Dekkers, Nicolaas P. A. Zuithoff, Daphne S. Bakker, et al.
Allergy (2024)
Closed Access
Coco Dekkers, Nicolaas P. A. Zuithoff, Daphne S. Bakker, et al.
Allergy (2024)
Closed Access
Erythrodermic atropic dermatitis responding to tralokinumab after dupilumab failure
Aida Lara-Moya, Vicente Exposito-Serrano, Patricia Garbayo‐Salmons, et al.
Indian Journal of Dermatology Venereology and Leprology (2024), pp. 1-3
Open Access
Aida Lara-Moya, Vicente Exposito-Serrano, Patricia Garbayo‐Salmons, et al.
Indian Journal of Dermatology Venereology and Leprology (2024), pp. 1-3
Open Access
Association between IL-25, IL-33 and atopic dermatitis: A systematic review and meta-analysis
Boyang Zhou, Xueping Yue, Surong Liang, et al.
European Journal of Inflammation (2023) Vol. 21
Open Access
Boyang Zhou, Xueping Yue, Surong Liang, et al.
European Journal of Inflammation (2023) Vol. 21
Open Access
